Abstract
Dysfunction of P/Q-type calcium channels is thought to underlie a variety of neurological diseases. There is evidence that migraine, Alzheimer’s disease, and epilepsy involve a gain-of-function of the channel, leading to abnormal presynaptic vesicle release. P/Q-channel blockers may normalize current flow and consequently lead to an alleviation of disease symptoms. Although the medical need is high, there are no such compounds on the market.
Here we describe a high throughput screen (HTS) for P/Q-type calcium channel blockers and the confirmation of hits by automated electrophysiology. We generated a HEK293 cell line stably expressing the α1A subunit of the P/Q-type calcium channel under control of a tetracycline (Tet) promoter. The accessory β1.1 and α2δ1 subunits were co-expressed constitutively. The cell line was pharmacologically characterized by ion channel specific modulators, and revealed functional P/Q-type calcium currents. Using a fluorescence imaging plate reader (FLIPR), an assay for P/Q-type calcium channels was established based on a calcium sensitive dye. HTS of a 150,000 compound-containing sub-library led to the identification of 3262 hits that inhibited the fluorescence signal with potencies below 10 μM. Hit-to-lead (HTL) efforts identified 12,400 analogues. Compounds were clustered into 37 series, and 8 series of interest were prioritized.
An electrophysiological secondary screen, providing a more direct measure of channel function, was implemented into the HTL process. 27 selected exemplars of different chemotypes were validated by automated whole-cell patch clamp analysis at inactivated channel state.
The discovery of P/Q-channel blockers may foster the development of new therapeutics for a variety of neurological diseases.
Keywords: Automated patch-clamp, electrophysiology, FLIPR, high throughput screening, P/Q-type voltage-gated calcium channel, tetracycline-dependent expression
Combinatorial Chemistry & High Throughput Screening
Title:Development and Validation of a Fluorescence-Based HTS Assay for the Identification of P/Q-Type Calcium Channel Blockers
Volume: 15 Issue: 5
Author(s): Mario Mezler, David Hermann, Andrew M. Swensen, Andreas Draguhn, Georg C. Terstappen, Gerhard Gross, Hans Schoemaker, Gail Freiberg, Steve Pratt, Sujatha M. Gopalakrishnan and Volker Nimmrich
Affiliation:
Keywords: Automated patch-clamp, electrophysiology, FLIPR, high throughput screening, P/Q-type voltage-gated calcium channel, tetracycline-dependent expression
Abstract: Dysfunction of P/Q-type calcium channels is thought to underlie a variety of neurological diseases. There is evidence that migraine, Alzheimer’s disease, and epilepsy involve a gain-of-function of the channel, leading to abnormal presynaptic vesicle release. P/Q-channel blockers may normalize current flow and consequently lead to an alleviation of disease symptoms. Although the medical need is high, there are no such compounds on the market.
Here we describe a high throughput screen (HTS) for P/Q-type calcium channel blockers and the confirmation of hits by automated electrophysiology. We generated a HEK293 cell line stably expressing the α1A subunit of the P/Q-type calcium channel under control of a tetracycline (Tet) promoter. The accessory β1.1 and α2δ1 subunits were co-expressed constitutively. The cell line was pharmacologically characterized by ion channel specific modulators, and revealed functional P/Q-type calcium currents. Using a fluorescence imaging plate reader (FLIPR), an assay for P/Q-type calcium channels was established based on a calcium sensitive dye. HTS of a 150,000 compound-containing sub-library led to the identification of 3262 hits that inhibited the fluorescence signal with potencies below 10 μM. Hit-to-lead (HTL) efforts identified 12,400 analogues. Compounds were clustered into 37 series, and 8 series of interest were prioritized.
An electrophysiological secondary screen, providing a more direct measure of channel function, was implemented into the HTL process. 27 selected exemplars of different chemotypes were validated by automated whole-cell patch clamp analysis at inactivated channel state.
The discovery of P/Q-channel blockers may foster the development of new therapeutics for a variety of neurological diseases.
Export Options
About this article
Cite this article as:
Mezler Mario, Hermann David, M. Swensen Andrew, Draguhn Andreas, C. Terstappen Georg, Gross Gerhard, Schoemaker Hans, Freiberg Gail, Pratt Steve, M. Gopalakrishnan Sujatha and Nimmrich Volker, Development and Validation of a Fluorescence-Based HTS Assay for the Identification of P/Q-Type Calcium Channel Blockers, Combinatorial Chemistry & High Throughput Screening 2012; 15 (5) . https://dx.doi.org/10.2174/138620712800194503
DOI https://dx.doi.org/10.2174/138620712800194503 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Advances in the design of antibody & protein with conformational dynamics and artificial intelligence approaches
“Antibodies & Protein Design” section focuses on the utilization of multiple strategies to engineer and optimize antibodies and proteins that serve diverse analytical strategies, such as combinatorial protein design, structure-based design, sequence-based design, and other techniques that incorporate principles of protein-protein interactions, allosteric regulation, and post-translational modifications. Example applications include ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute-force experimentation, which can be time-consuming and resource-intensive. Spectral graph theory, a branch of mathematics dealing with the properties of graphs in relation to the eigenvalues and eigenvectors of matrices associated ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of <i>Saurauia roxburghii</i> Wall. (Actinidiacaea) as a Traditional Medicinal Plant, Its Phytochemical Study and Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Emerging Signalling and Protein Interactions Mediated Via Metabotropic Glutamate Receptors
Current Drug Targets - CNS & Neurological Disorders Machine Learning, Molecular Modeling, and QSAR Studies on Natural Products Against Alzheimer’s Disease
Current Medicinal Chemistry Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials
Current Pharmaceutical Design Method Development and Validation of a Novel UHPLC Coupled with MS/MS System for the Estimation of Brivaracetam in Human (K2EDTA) Plasma Samples and its Application to Pharmacokinetic Study
Current Pharmaceutical Analysis Editorial [Hot topic: Pharmacotherapies for Alcoholism: The Old and the New (Guest Editor: M. Foster Olive)]
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 6
Current Topics in Medicinal Chemistry Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Therapeutic Drugs that Slow the Heart Rate of Early Rat Embryos. Is there a Risk for the Human?
Current Pharmaceutical Design Patents on Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?
Current Medicinal Chemistry Induction of Serine Racemase Expression and D-Serine Release from Microglia by Secreted Amyloid Precursor Protein (sAPP)
Current Alzheimer Research Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications
Current Neuropharmacology Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Review of Somnambulism in Children
Current Pediatric Reviews Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease
Current Pharmaceutical Design In Vivo MRI in Different Models of Experimental Epilepsy
Current Drug Targets Editorial [Hot Topic: Recent Developments in the Drug Discovery of Epilepsy (Guest Editor: Waquar Ahsan)]
Current Topics in Medicinal Chemistry Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease
Current Alzheimer Research